Glenmark Makes Progress On Favipiravir Clinical Trials
FabiFlu Could Prevent Patients From Progressing To ARDS
The Phase III clinical trials of Glenmark’s FabiFlu demonstrate that the oral antiviral could prevent mild and moderate Covid-19 patients from progressing to acute respiratory distress syndrome or dying. Glenmark plans to release the clinical trial data soon.
